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Abstract 
Sleep and wakefulness are highly complex processes that are elegantly orchestrated by fine-
tuned neurochemical changes among neuronal and non-neuronal ensembles, nuclei and networks of 
the brain. Important neurotransmitters and neuromodulators regulating the circadian and 
homeostatic facets of sleep-wake physiology include melatonin, γ-amino-butyric acid, hypocretin, 
histamine, norepinephrine, serotonin, dopamine, and adenosine. Dysregulation of these 
neurochemical systems may cause sleep-wake disorders, which are commonly classified into 
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insomnia disorder, parasomnias, circadian rhythm sleep-wake disorders, central disorders of 
hypersomnolence, sleep-related movement disorders, and sleep-related breathing disorders. Sleep-
wake disorders can have far reaching consequences on physical, mental and social well-being and 
health and, thus, need be treated with effective and rational therapies. Apart from behavioral (e.g., 
cognitive behavioral therapy for insomnia), physiological (e.g., chronotherapy with bright light), and 
mechanical (e.g., continuous positive airway pressure treatment of obstructive sleep apnea) 
interventions, pharmacological treatments often are the first-line clinical option to improve 
disturbed sleep and wake states. Nevertheless, not all patients respond to pharmacotherapy in 
uniform and beneficial fashion. The improved understanding of the neurochemical mechanisms 
regulating sleep and wakefulness and the mode of action of sleep-wake therapeutics has provided a 
conceptual framework, to search for functional genetic variants modifying individual drug response 
phenotypes. This article will summarize the currently known genetic polymorphisms that modulate 
drug sensitivity and exposure to partly determine individual responses to sleep-wake 
pharmacotherapy. In addition, a pharmacogenetic strategy will be outlined how based upon classical 
and opto-/chemogenetic strategies in animals, as well as human genetic associations, circuit 
mechanisms regulating sleep-wake functions in humans can be identified. As such, experimental 
human sleep-wake pharmacogenetics forms a bridge spanning basic research and clinical medicine 
and constitutes an essential step for the search and development of novel sleep-wake targets and 
therapeutics. 
 
Keywords 
Polymorphism; pharmacokinetics; pharmacodynamics; circadian; melatonin; GABA; orexin; H3 
receptor; adenosine; dopamine  
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Introduction 
Wakefulness and sleep are complex behavioral processes, which are elegantly orchestrated 
by fine-tuned interactions of neurotransmitter and neuromodulator systems within defined wake-
sleep circuits of the brain. Over the past 100 years, clinical observations in patients suffering from 
sleep-wake disorders and basic research spanning from in vitro preparations and animal models to 
healthy human volunteers, have led to a widely accepted neurobiological model underlying the 
physiological alterations between wakefulness and distinct sleep states (for review, see (Holst et al., 
2016)). More specifically, wakefulness and cortical arousal are thought to be governed primarily by 
concerted activity in upper brain stem and hypothalamic nuclei, which produce acetylcholine (Ach), 
norepinephrine (NE), serotonin (5-HT; 5-hydroxy-tryptamine), dopamine (DA), histamine (His) and 
hypocretin (Hcrt; aka orexin) as their neurotransmitters. These nuclei activate thalamus, cortex and 
spinal cord, and inhibit the sleep-promoting ventro-lateral preoptic (VLPO) area of the 
hypothalamus. 
The regulation of sleep differs substantially between the non-rapid-eye-movement (NREM) 
and rapid-eye-movement (REM) sleep states. NREM sleep is supposed to be promoted by GABA- (γ-
amino-butyric acid) and galanin-containing neurons originating in VLPO and median preoptic nuclei 
of the hypothalamus. These nuclei inhibit the wake-promoting arousal systems described above. On 
the other hand, REM sleep exhibits both, ‘wake-like’ and ‘sleep-like’ characteristics. ‘Wake-on’-‘REM-
on’ basal forebrain (BF) and brain stem nuclei containing Ach and glutamate activate the BF and 
cortex, induce muscle atonia, and promote rapid eye movements. In addition, hypothalamic neurons 
containing melanin-concentrating hormone suppress the activity of ‘Wake-on’-‘REM-off’ cell groups, 
which primarily include the upper brainstem monoaminergic nuclei. 
Powerful new tools to interrogate sleep-wake regulating circuits, including sophisticated 
optogenetic and chemogenetic experiments, have revealed new molecular and cellular markers, as 
well as novel network mechanisms and pathways in sleep-wake regulation. These recent insights 
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may necessitate an adaptation of the basic sleep-wake neurochemistry described above. They have 
been discussed in comprehensive reviews and other chapters of this book (Adamantidis and Luthi, 
2018 ; Saper and Fuller, 2017; Tyree and de Lecea, 2017; Eban-Rothschild et al., 2018; Luppi and 
Fort, 2018; Varin and Bonnavion, 2018), and are not the focus of this chapter. In this article, firstly, 
genetic aspects of the current pharmacotherapy of sleep-wake disorders will be reviewed. Secondly, 
an experimental pharmacogenetic strategy to identify circuit mechanisms underlying sleep-wake 
regulation in humans will be outlined. 
 
Current Sleep-wake Pharmacotherapy  
Based on the ‘standard model’ of sleep-wake circuitry, subtle changes in important 
neurotransmitters and neuromodulators (including NE, 5-HT, DA, His, Hcrt, melatonin, glutamate, 
Ach, GABA, and adenosine) regulate not only the transitions among the behavioral states 
wakefulness, REM sleep and NREM sleep, but also their maintenance (Holst and Landolt, 2018). 
Dysregulation of these fine-tuned neurochemical systems can lead to sleep-wake disturbances. 
According to the 3rd edition of the International Classification of Sleep Disorders, sleep-wake 
disturbances are subdivided into the following major diagnostic sections: insomnia disorder, 
circadian rhythm sleep-wake disorders, sleep-related breathing disorders, sleep-related movement 
disorders, central disorders of hypersomnolence, parasomnias, and other sleep disorders (2014). 
Some of these pathologies are typically treated with pharmacological agents as summarized and 
reviewed in Part III of this book (insomnia and circadian rhythm sleep-wake disorder: (Spiegelhalder 
et al.); hypersomnias and sleep-related movement disorders: (Baumann, 2018)). All drugs presently 
used to treat the symptoms of sleep-wake disorders interfere with the neurochemical and 
neuromodulatory systems mentioned above (Idzikowski, 2014; Holst et al., 2016). Thus, although the 
‘standard model’ of the neuroanatomical and neurochemical regulation of wakefulness and sleep 
will have to be adapted, it provides a useful conceptual framework for understanding the effects of 
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the medications currently used to improve sleep and wake states (Figure 1). 
 
Insomnia Disorder 
Drug treatment is often used for short-term alleviation of insomnia symptoms. When 
combined with behavioral therapy, pharmacological treatments show durable improvements in 
sleep patterns (Riemann and Perlis, 2009). Conceptually, disturbed sleep can be pharmacologically 
improved by compounds that either promote sleep or dampen the wake-promoting systems. 
Agonistic modulators of GABAA receptors such as benzodiazepines and Z-drugs (e.g., 
zolpidem) enhance the inhibitory inputs of GABA-containing neurons that inhibit the ascending 
arousal pathways (Finelli et al., 2000). These compounds act as positive allosteric modulators and, at 
higher doses, as agonists of GABAA receptors. They are often prescribed for the short-term 
pharmacological treatment of insomnia disorder and show demonstrated efficacy in shortening 
sleep latency and improving sleep maintenance (Dresler et al., 2014). Absolute effect sizes, however, 
may be rather small when compared to placebo (Wilt et al., 2016). In standard clinical practice of 
pharmacologically treating insomnia, benzodiazepines and Z-drugs have largely replaced the 
previously used barbiturates.  
The dual orexin receptor antagonist (DORA), suvorexant, was recently approved by the US 
Food and Drug Administration (FDA) for treating insomnia disorder in adults (Wilt et al., 2016). 
Suvorexant acts by antagonizing wake-promoting Hcrt neurons located in the lateral hypothalamus. 
Some authors claim that surovexant elicits more physiological sleep than benzodiazepines (Patel et 
al., 2015). Nevertheless, the compound seems to mainly prolong REM sleep and stage 2 sleep, with 
marginal effect on deep slow wave sleep (Hoyer and Jacobson, 2013). 
Drugs antagonizing key monoaminergic nuclei of the ascending arousal pathways commonly 
cause sleepiness. One example of such a mode of action is the blockade of H1 receptors to 
antagonize wake promotion by His. ‘Antihistamines’ such as diphenhydramine and doxylamine have 
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long been available over-the-counter and are sometimes used to treat insomnia. Similarly, tricyclic 
and heterocyclic antidepressants and antipsychotics are often associated with sleepiness, probably 
related to their antihistamine and possibly other “off-target” receptor interactions (such as 
anticholinergic effects). Low doses of doxepin are FDA-approved to treat insomnia by promoting 
sleep onset (Goforth, 2009). Other sedating antidepressant and antipsychotic medications are more 
and more commonly prescribed “off-label” as sleeping pills (Proctor and Bianchi, 2012; Krystal et al., 
2013). Apart from H1 and muscarinic ACh receptors, some of these agents (e.g., mirtazapine) have 
high affinity for 5-HT2A and adrenergic α1 receptors. Blockade of these receptors facilitates sleep. 
Conversely, these compounds often also inhibit 5-HT and NE re-uptake transporters and antagonize 
5-HT2C and α2 receptors and thus promote wakefulness, which detracts from the sleep-promoting 
effects of blocking the H1 receptors (Krystal et al., 2013). 
 
Parasomnias 
The most commonly used drugs for NREM sleep parasomnias are intermediate- and long-
acting benzodiazepines and antidepressants (Castelnovo et al., 2018). The pharmacologic treatment 
of REM sleep behavior disorder presently relies primarily on the benzodiazepine, clonazepam, 
whereas melatonin and melatonin receptor agonists may be equally efficacious with less unwanted 
effects (McGrane et al., 2015; Castelnovo et al., 2018). 
 
Circadian Rhythm Sleep-Wake Disorders 
The circadian resetting effects of melatonin are well documented. Interference with both 
melatonin MT1 and MT2 receptor subtypes, contributes to the distinct phase-response profile of 
melatonin (Burgess and Emens, 2018). Melatonin alone or in combination, as well as different 
melatonin analogues, are available either without prescription or as regulatory-approved drugs. 
There is increasing interest in the potential of melatonin-based therapies in the treatment of 
Landolt et al. Human Sleep-Wake Pharmacogenetics 
8 
disturbed sleep (Alston et al., 2018). These therapies offer potential to treat sleep and mood 
disorders, especially when circadian rhythm disturbances are also present. Such disorders include 
insomnia induced by shifted sleep-wake cycles in healthy individuals, insomnia in older adults, 
delayed sleep-wake phase disorder, non-24-hour sleep-wake disorder (N24HSWD), seasonal 
affective disorder, and major depressive disorder (Alston et al., 2018; Burgess and Emens, 2018). 
Prolonged-release melatonin (Circadin®) has been approved for chronic insomnia in patients older 
than 55 years. In combination with antihistamines, GABA-ergic hypnotics, herbal extracts, or bright 
light therapy, prolonged-release melatonin may improve hypnotic efficacy (Saxvig et al., 2014; Rivara 
et al., 2015). Apart from N24HSWD, the MT1/2 receptor agonist, tasimelteon, may also be useful in 
certain patients with insomnia, advanced-sleep-phase-syndrome and delayed-sleep-phase-syndrome 
(Lankford, 2011). Ramelteon received FDA-approval for treatment of insomnia in older adults, and 
the MT1/2 agonist/5-HT2C receptor antagonist, agomelatine, has EMA- and TGA (Therapeutic Goods 
Administration, Australia)-approval for major depressive disorder. Agomelatine phase shifts the 
circadian system and improves sleep in depressed patients, although its usefulness for primary sleep 
disorders is debated (De Berardis et al., 2015). 
 
Central Disorders of Hypersomnolence 
Central disorders of hypersomnolence are characterized by excessive daytime sleepiness 
(EDS), often despite apparently normal quality, duration and timing of nocturnal sleep. These 
disorders include narcolepsy type-1 (characterized by deficient Hcrt in cerebrospinal fluid), 
narcolepsy type-2 and idiopathic hypersomnia. Their pharmacological treatment focuses on the 
management of EDS, with additional treatment of cataplexy, which is typically present in patients 
with narcolepsy type-1 (Baumann, 2018). 
Modafinil and its (R)-enantiomer, armodafinil, are FDA-approved first-line treatments of EDS 
in narcolepsy (Mignot, 2012; Abad and Guilleminault, 2017). While the mode of action of 
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(ar)modafinil is complex and may involve NE, 5-HT, His, Hcrt, glutamate, and GABA, it increases DA-
ergic neurotransmission and blocks the DA re-uptake transporter (DAT) (Wisor et al., 2001; Volkow 
et al., 2009; Wisor, 2018). 
Amphetamine and its derivatives are treatments of second-choice against EDS in narcolepsy 
(Abad and Guilleminault, 2017). These compounds actively promote the presynaptic release of DA 
and dampen DAT function (Mignot, 2012). They cause autonomic arousal and psychomotor agitation 
and have strong addictive properties. Stimulants such as methylphenidate and mazindol are specific 
DAT inhibitors. Methylphenidate is FDA-approved for narcolepsy. Preliminary evidence also suggests 
therapeutic efficacy for mazindol (Nittur et al., 2013). 
Certain antidepressants such as bupropion, venlafaxine and clomipramine that block the re-
uptake transporters for DA (DAT), NE (NET) and/or 5-HT (SERT) are typically used against cataplexy in 
narcolepsy type-1 (Mignot, 2012). Tricyclic antidepressants strongly reduce REM sleep and 
cataplectic attacks without affecting EDS (Houghton et al., 2004). They have undesired 
anticholinergic and antihistaminic properties and prolonged use can cause tolerance. Dual NET-SERT 
inhibitors or selective NE and 5-HT re-uptake inhibitors (SSRIs) may provide alternative options to 
treat cataplexy (Houghton et al., 2004). Finally, monoamine oxidase (MAO) inhibitors such as 
selegiline are used ‘off-label’ against cataplexy and EDS (Thorpy and Dauvilliers, 2015). 
The adenosine A1 and A2A receptor antagonist, caffeine, is the most widely used stimulant 
worldwide. Caffeine can improve vigilance in susceptible, sleep deprived individuals (Gottselig et al., 
2006; Rétey et al., 2007), yet probably has insufficient potency in patients with clinical EDS (Banerjee 
et al., 2004). Sleepy people may use caffeine excessively to improve alertness (Urry et al., 2017), and 
a positive correlation between disease severity and habitual caffeine use was observed in patients 
with narcolepsy-cataplexy (Mitler et al., 1998). Intake of 200-300 mg per day, which is typical in 
Western societies, is generally well tolerated and does not posit a known health risk (Loftfield et al., 
2018). 
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The safe improvement of wakefulness in hypersomnolent patients has so far proved difficult, 
despite the fact that the above-mentioned compounds are potent. Based on the rationale that sleep 
and wakefulness form a functional continuum and that improved sleep also improves the quality of 
wakefulness, -hydroxy-butyrate (GHB or the sodium salt of -hydroxy-butyric acid, sodium oxybate), 
is currently the first-line, FDA-approved agent for cataplexy and EDS in patients with narcolepsy 
(Thorpy and Dauvilliers, 2015; Abad and Guilleminault, 2017). This rapid sedative may also alleviate 
sleep disruption in narcolepsy. The exact mode of action of GHB is unknown. GHB is an endogenous 
short-chain fatty acid that exhibits high affinity for GHB receptors (KD ≈ 30-580 nM) and low affinity 
for GABAB receptors (KD ≈ 2.6-16 μM) (Mamelak, 2009). The stabilization of sleep continuity by 
supra-physiological doses of GHB may be predominantly mediated by agonistic stimulation of GABAB 
receptors. Thus, the GABAB receptor agonist, baclofen, may also be useful in treating patients with 
narcolepsy (Huang and Guilleminault, 2009; Black et al., 2014). 
Histamine H3 receptor inverse agonists such as pitolisant provide a promising new class of 
wake-promoting medications with possible pro-cognitive properties (Stocking and Letavic, 2008). 
The H3 receptor is an inhibitory auto-receptor on pre-synaptic neurons, which attenuates the release 
of His and other excitatory neurotransmitters when activated (Lin et al., 2011). 
It has been postulated that Hcrt neurons continuously integrate information from multiple 
processes, to modulate the propensity to stay awake or to fall asleep (Eban-Rothschild et al., 2018). 
The firing of Hcrt neurons in the lateral/posterior hypothalamus promotes wakefulness. Intra-nasal 
delivery of Hcrt peptide may reduce wake-REM sleep transitions and slightly improve attention after 
sleep in patients with narcolepsy-cataplexy (Weinhold et al., 2014). 
 
Sleep-Related Movement Disorders 
The pharmacologic treatment of restless legs syndrome (RLS) and periodic limb movement 
disorder during sleep traditionally relies on the dopamine D2 receptor antagonists pramipexole, 
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ropinirole and rotigotine (Baumann, 2018). These dopaminergic agents, and in particular L-dopa, 
carry the risk of augmentation, i.e., aggravated RLS symptoms with continued medication use 
(Trenkwalder and Paulus, 2010). Iron supplementation in case of iron deficiency, benzodiazepines, 
and opiates may also be effective and are often used as secondary treatments (Winkelmann et al., 
2018).  Prolonged-release oxycodone-naloxone, a combined opioid analgesic and opioid receptor 
antagonist, has recently provided an additional option for refractory RLS (Trenkwalder et al., 2013). 
Because of the frequently observed augmentation with dopaminergic agents, an 
international task force recently recommended α2β receptor ligands of voltage-gated calcium 
channels, such as gabapentin and pregabalin, as first‐line option to treat restless legs (Garcia-
Borreguero et al., 2016). Gabapentin and pregabalin are structurally related to GABA, increase GABA 
concentration the human brain (Cai et al., 2012), and inhibit calcium currents. The derivative 
gabapentin-enacarbil was recently approved by FDA for RLS. In contrast to the dopaminergic drugs, 
gabapentin-enacarbil does not lead to augmentation. 
Based on the hypothesis that brain iron deficiency in RLS is associated with a hypo-
adenosinergic state, a preliminary study recently suggested that the non-selective ENT1/ENT2 
(equilibrative nucleoside transporter) inhibitor, dipyridamole, has significant therapeutic effects on 
sensory and motor symptoms, as well as sleep (Garcia-Borreguero et al., 2018). 
 
Sleep-Related Breathing Disorders 
Sleep-related breathing disorders include upper airway obstructions (obstructive sleep 
apnea [OSA]) and ceased or decreased ventilatory effort (central sleep apnea) during sleep. While 
OSA is most commonly treated with continuous positive airway pressure (CPAP) therapy, the 
therapeutic success of CPAP and other available therapies is often hampered by limited compliance 
or efficacy (Hedner and Zou, 2018). These and other reasons warrant the scientific search for 
pharmacological remedies of OSA. Nevertheless, currently no pharmacologic alternatives to CPAP 
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are available. Promising research has recently characterized different phenotypes of OSA, which may 
provide novel strategies and targets for drug development (Hedner and Zou, 2018). 
 
Variable Drug Response Genetics 
Gene polymorphisms modulating drug sensitivity and exposure can determine individual responses 
It has long been recognized that not all patients respond to pharmacotherapy in a uniform 
and beneficial fashion. How a therapeutic compound affects the organism and its physiology 
(pharmacodynamics) and how the organism acts on such a compound (pharmacokinetics) are highly 
individual processes, which are, in part, genetically determined. Pharmacogenetic approaches aim at 
elucidating genetically determined inter-individual differences in drug responses, with the goal to 
discriminate responders from non-responders and to minimize toxicity and adverse drug reactions. 
Such studies have shown that single nucleotide polymorphisms (SNPs), variable-number-tandem-
repeat (VNTR) polymorphisms, copy number variations, and insertions/deletions in genes regulating 
the pharmacodynamics (e.g., receptors, ion channels, enzymes, immune molecules) of medications 
and/or their pharmacokinetics (e.g., metabolizing enzymes, transporters, plasma protein binding) 
contribute to wanted and adverse actions of pharmacotherapeutic agents (Evans and Relling, 1999; 
Sadee and Dai, 2005; Roden et al., 2011; Holst et al., 2016). 
Genes modulating the pharmacodynamic response to a pharmacological treatment may 
code for the direct targets of drugs (e.g., receptors) or for proteins that synthesize, clear or degrade 
the endogenous ligands of these targets (e.g., neurotransmitters). Functional genetic variation in 
these genes, thus, possibly affects drug sensitivity. 
The field of pharmacogenetics has historically focused on genetically determined differences 
in the activity of drug-metabolizing enzymes. Functional variants of genes encoding such enzymes 
can modulate exposure to therapeutic agents and, thus, their efficacy and toxicity. For example, 
more than 80 % of all clinically used drugs are metabolized by cytochrome-P450 (CYP) isoenzymes 
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that are encoded in humans by 57 genes of 3 major families (Ingelman-Sundberg, 2004). Functional 
variants of the CYP1A2, CYP2D6, CYP2C8/9, CYP2C19 and CYP3A4/5 genes are of particular interest 
because they have been associated with altered clinical outcomes (Evans and Relling, 1999; 
Ingelman-Sundberg, 2004). Other known genetic variants affecting drug exposure include 
conjugation enzymes, such as uridine-5'-diphospho-glucuronosyltransferase (UGT) and N-
acetyltransferase 2 (NAT2), and drug transporters, including solute carrier (SLC) and ATP-binding 
cassette (ABC) transporter families (Kerb, 2006). 
The main targets for the wanted effects, as well as the main metabolism and excretion 
pathways of the sleep-wake therapeutics introduced in the previous paragraphs are summarized in 
Table 1. In the following section, known genetic differences in pharmacodynamics and 
pharmacokinetics of these drugs and drug classes will be reviewed. The contents of this section have 
been elaborated and updated based on a recent comprehensive overview (Holst et al., 2016). For 
that purpose, PubMed searches were performed between March 2015 and July 2018, including as 
search terms all generic drug names mentioned below AND (‘pharmacogenetics’ OR ‘polymorphism’ 
OR ‘CYP’ OR ‘therapy’). A total of 79 references was identified, yet those articles whose content was 
unrelated to the present review are not cited here. 
 
Pharmacotherapy of Insomnia Disorder and Parasomnias 
Benzodiazepines, Z-drugs and barbiturates 
Genetic variants of the α subunits of GABAA receptors alter the sensitivity to 
benzodiazepines and Z-drugs in transgenic animals (Tobler et al., 2001; Cope et al., 2004; Kopp et al., 
2004), the treatment responses to antiepileptic drugs (Hung et al., 2013), and the sensitivity towards 
diazepam in alcoholic patients (Iwata et al., 1999). No studies on the relevance of GABAA receptor 
polymorphisms for variable hypnotic effects of benzodiazepines and Z-drugs in insomnia patients are 
currently available. 
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Most benzodiazepines and Z-drugs are degraded by CYP3A4/5 and CYP2C19 isoenzymes 
(Hohmann et al., 2016). Genetic variants of these enzymes affect the pharmacokinetics of various 
members of these drug classes (Park et al., 2006; Shen et al., 2013). Indeed, individual CYP 
isoenzyme metabolizer status is important for the correct dosing of these hypnotics, to optimize 
efficacy and avoid adverse actions, such as daytime impairment and next-morning sedation 
(Lozupone et al., 2017). 
Some benzodiazepines (e.g., lorazepam, clonazepam, nitrazepam) are glucuronidated by 
UGT isoenzymes or acetylated by NAT2. Glucuronidation is a xenobiotic elimination reaction mainly 
occurring in the liver. Polymorphisms in some UGT genes affect lorazepam clearance. One case 
documented prolonged sedation after lorazepam, due to absence of the isoenzyme UGT2B7 (Siller et 
al., 2014). Furthermore, NAT2 polymorphisms causing “slow acetylator” phenotypes impair the 
metabolism of clonazepam in vitro (Toth et al., 2016). 
 
Dual orexin receptor antagonists 
While genetic variants of HCRTR1/2 receptors and Hcrt synthesis are frequent (Thompson et 
al., 2014), their functional and pharmacological significance are not well understood. The current 
development of Hcrt receptor antagonists as novel hypnotics should take these genetic variants into 
account, to better understand the variability in drug efficacy and side effects (Hoyer and Jacobson, 
2013; Thompson et al., 2014). For example, in vitro and in vivo characterization of the metabolism 
and disposition of suvorexant in humans determined that CYP3A4/5 are the predominant enzymes 
mediating oxidation of this compound (Cui et al., 2016). 
 
Antihistamines 
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Large inter-individual differences are observed in the sedative effects of diphenhydramine, 
which appear to be due to drug metabolism rather than genetic variants of His receptors. The 
isoenzymes CYP2D6, CYP1A2, CYP2C9, and CYP2C19 contribute to diphenhydramine metabolism 
(Akutsu et al., 2007). Three CYP2D6 ultra-metabolizers reported paradoxical excitation rather than 
sedation on diphenhydramine treatment (de Leon and Nikoloff, 2008), and the CYP2D6*10 allele 
was identified as a risk factor for antihistamine-induced sleepiness in Japanese adults (Saruwatari et 
al., 2006). 
 
Sedating antidepressants and antipsychotics 
Pharmacogenetic studies of mirtazapine established several polymorphisms that modulate 
its hypnotic and antidepressant efficacy. For example, the c.-998G>A polymorphism (SNP-Id: rs6311) 
of the gene encoding the 5-HT2A receptor (HTR2A) determined mirtazapine-induced sleep 
improvements in patients with major depressive disorder (MDD) (Kang et al., 2007). Mirtazapine also 
binds to DA, NE and ACh receptors. Consistent with this pharmacological profile, also rs28363170 of 
the DAT1 gene encoding the dopamine transporter (DAT; aka SLC6A3, solute carrier family 6 
member 3), and distinct polymorphisms of ARRB1 (β arrestin 1), COMT (catechol-O-
methyltransferase), MAOA and MAOB (monoamine oxidase isoenzymes A and B) genes affect 
responses to mirtazapine in patients with MDD (reviewed in (Holst et al., 2016)). These studies 
illustrate that sleep-promoting agents may act on multiple systems, and polymorphisms of genes 
regulating different neurotransmitters may mutually influence the efficacy of a given drug. 
Polymorphisms of the HTR2A gene were also associated with treatment outcomes in 
depressed patients treated with SSRIs (Kato and Serretti, 2010). The variants c.371T>C of HTR1B (5-
HT1B receptor; SNP-Id: rs130060) and c.102C>T of HTR2A (SNP-Id: rs6313) affect binding affinity of 
the 5-HT2A receptor antagonist, ketanserin (Brüss et al., 1999; Holmes et al., 2007). These 
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polymorphisms may modulate slow wave sleep promotion by 5-HT2A receptor antagonists currently 
in development as novel hypnotics. 
Apart from genetic differences in drug targets, genetically determined metabolizer status 
modifies clearance of doxepin (metabolized by CYP2D6, CYP2C9 and CYP2C19) (Kirchheiner et al., 
2002) and (es)mirtazapine (primarily metabolized by CYP2D6) (Brockmöller et al., 2007). Fatal 
poisoning with both drugs was associated with defective CYP2D6 enzymes (Neukamm et al., 2013). 
Nevertheless, systematic review of the data indicates that more data are needed to conclude that 
CYP2D6 poor metabolizers are more prone to adverse effects of doxepin (Haufroid and Hantson, 
2015). Driving performance in healthy volunteers was more impaired after esmirtazapine 
administration in poor rather than in rapid CYP2D6 metabolizers (Ramaekers et al., 2011). 
 
Pharmacotherapy of Circadian Rhythm Sleep-Wake Disorders 
Melatonin and melatonin analogues 
Several polymorphisms in the melatonin receptor genes, MTNR1A and MTNR1B, were 
identified (Ekmekcioglu, 2006), and MT2 receptor gene variants were associated with type-2 
diabetes (Karamitri et al., 2013). One study suggested a relevant association between polymorphism 
rs2119882 of MTNR1A (proposed to affect promoter activity) and insomnia symptoms in 
schizophrenia (Park et al., 2011). The development of melatonin receptor agonists for insomnia and 
circadian rhythm sleep-wake disorders would benefit from pharmacogenetic studies, taking into 
account functional polymorphisms of melatonin receptors. 
Melatonin is synthesized from 5-HT, metabolized in the liver almost exclusively by CYP1A2, 
and excreted as sulfphatoxymelatonin in urine (Claustrat et al., 2005). The plasma concentration of 
melatonin after oral ingestion was higher in individuals with *1A/*1A than with *1F/*1F genotypes 
of CYP1A2 (Härtter et al., 2006). Furthermore, autistic patients with slow CYP1A2 metabolism due to 
*1F/*1A or *1A/*1A genotypes showed decreasing potency of melatonin to improve sleep problems 
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(Braam et al., 2013). Finally, Chinese carriers of a *1A and other CYP1A2 variants appear to 
metabolize agomelatine more slowly than carriers of the *1F allele (Song et al., 2014). Interestingly, 
sulphatoxymelatonin was recently proposed as a potential biomarker of brain 5-HT status in severe 
genetic disorders affecting 5-HT biosynthesis (Batllori et al., 2017). 
 
Pharmacotherapy of Central Disorders of Hypersomnolence 
(Ar)Modafinil and stimulants 
Individual effects of standard doses of (ar)modafinil and stimulants such as methylphenidate 
and amphetamines have been associated with genetic variants of proteins regulating endogenous 
neurotransmitter degradation and transmission. For example, the activity of the monoamine-
metabolizing enzyme, COMT, depends on several known genetic variants, including the functional 
c.472G>A (p.Val158Met) polymorphism (SNP-Id: rs4680) (Chen et al., 2004). This common valine-to-
methionine substitution drastically reduces enzymatic activity, leading to elevated prefrontal cortex 
(PFC) dopaminergic tone in Met/Met homozygotes when compared to Val/Val homozygotes 
(Tunbridge et al., 2006). The treatment response with modafinil in narcolepsy patients differs widely 
among COMT genotypes. To control EDS, patients (female and male) with the Val/Val genotype of 
rs4680 need almost 100 mg more modafinil per day than patients with the Met/Met genotype 
(Dauvilliers et al., 2002). Intriguingly, as will be outlined below, the impact of this polymorphism on 
modafinil’s efficacy may be opposite in narcolepsy patients and sleep-deprived healthy volunteers. 
Apart from genetic variance modulating monoaminergic neurotransmission, variants in the 
gene encoding the P-glycoprotein drug transporter ABCB1 (ATP Binding Cassette Subfamily B 
Member 1) may partly explain individual therapeutic response to modafinil treatment in narcolepsy 
(Moresco et al., 2016). 
Both, the Val-allele of rs4680 of COMT and the 9R-allele of rs28363170 of DAT1 (see below) 
were associated with a pronounced response to methylphenidate (Kereszturi et al., 2008; Froehlich 
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et al., 2011) and enhanced risk of methamphetamine-induced psychosis and abuse (Ujike et al., 
2003; Li et al., 2004). Preliminary data further indicate that CYP2D6 extensive/ultra-rapid 
metabolizers could show an elevated risk for central nervous system risk adverse effects of 
methamphetamine (Haufroid and Hantson, 2015). Yet, more work is needed to confirm this 
association  
 
Venlafaxine 
Converging evidence from multiple studies indicates that CYP2D6 poor metabolizers are 
especially prone to adverse effects caused by venlafaxine (Haufroid and Hantson, 2015), whereas no 
significant association with clinical response was found with polymorphisms of the ABCB1 gene 
(Moresco et al., 2016). 
 
Caffeine 
Wake promotion and sleep disruption by the adenosine receptor antagonist, caffeine, are 
highly variable in patients and healthy people. The reasons for the pronounced inter-individual 
differences in caffeine effects on sleep remain incompletely understood. Shared environmental 
factors contribute to poor sleep quality associated with sustained high caffeine consumption (Treur 
et al., 2018). In addition, a population-based survey in roughly 1000 participants indicated that 
caffeine reduces sleep efficiency more potently in G/A allele carriers than in G/G homozygotes of 
polymorphism rs73598374 of the gene encoding the adenosine metabolizing enzyme, adenosine 
deaminase (Mazzotti et al., 2011). This study, however, was not controlled and awaits replication. 
Caffeine is mainly metabolized by CYP1A2, which shows 10- to 200-fold inter-individual 
differences in enzymatic activity (Fredholm et al., 1999; Gunes and Dahl, 2008). Consistent with the 
notion that the rate of caffeine metabolism is heritable (Rasmussen et al., 2002), a common C/A 
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polymorphism in intron 1 of the CYP1A2 gene (SNP-Id: rs762551) was found to affect caffeine half-
life in blood plasma, such that A/A-allele carriers (CYP1A2*1F) metabolize caffeine faster than C-
allele carriers (Sachse et al., 1999). Nevertheless, health status, gender and age, as well as lifestyle 
factors (such as habitual smoking and caffeine consumption, both known to induce CYP1A2 
enzymatic activity), also play important roles for the metabolism of caffeine to its primary 
metabolite, paraxanthine (e.g., Urry et al., 2016). 
Disturbed sleep causes some people to voluntarily abstain from caffeine. Genome-wide 
association (GWA) studies examined genetic contributions to caffeine consumption in humans. In 
47’341 participants of European descent, two polymorphisms regulating transcriptional activation of 
CYP1A2 determined habitual caffeine intake, one located in the bidirectional promoter region of the 
CYP1A1-CYP1A2 locus (SNP-Id: rs2470893) and one located in the aryl hydrocarbon receptor (AHR) 
(SNP-Id: rs4410790) gene (Cornelis et al., 2011). Intriguingly, a second study with more than 10’000 
participants of European ancestry, located two other polymorphisms in the same genes, rs2472297 
(CYP1A1-CYP1A2) and rs6968865 (AHR) (Sulem et al., 2011). These GWA studies support a role for 
CYP1A2 in the pharmacogenetics of caffeine. In addition, variants of ADORA2A (gene encoding 
adenosine A2A receptors) also influence caffeine preference (Cornelis et al., 2011) and sleep 
disruption by caffeine (Rétey et al., 2007; Byrne et al., 2012). 
Because melatonin is also degraded by CYP1A2, caffeine and melatonin compete for the 
same metabolizing enzyme. The half-life of caffeine during melatonin release may be prolonged and, 
in turn, caffeine consumption may delay the nocturnal peak of melatonin (Härtter et al., 2006; 
Braam et al., 2013). Habitual caffeine intake should, thus, be taken into account to understand 
individual efficacy of melatonin and novel melatonin receptor agonists. 
 
γ-Hydroxy-butyrate (GHB) 
In patients suffering from narcolepsy, GHB is currently used as first-line treatment of EDS 
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and cataplexy. So far, no studies have investigated the relevance of functional genetic variants of 
GABAB receptors nor polymorphisms related to GHB metabolizing pathways for individual drug 
responses in narcolepsy patients. By contrast, GHB intolerance was proposed to possibly arise from 
reduced activity of the GABA metabolizing enzyme, succinic semialdehyde dehydrogenase (Berner, 
2013). 
 
Pharmacotherapy of Sleep-Related Movement Disorders 
Dopamine D2/3 receptor agonists 
Polymorphisms of DRD2 and DRD3 genes (encoding dopamine D2 and D3 receptors) impact 
the effects of the dopamine receptor agonists used to treat RLS (Agundez et al., 2013). 
Pharmacogenetic evidence also linked a Ser9Gly polymorphism of DRD3 (SNP-Id: rs6280) with 
response to pramipexole in Parkinson’s disease (PD) patients, but not with the Taq1A polymorphism 
of DRD2 (SNP-Id: rs1800497) (Liu et al., 2009). In another study, however, both rs1800497 and a 
MspI polymorphisms of DRD3 (SNP-Id: rs4646996) were related to discontinued use of pramipexole 
and ropinirole in PD (Arbouw et al., 2009). 
The D2 receptor agonist ropinirole is degraded by CYP1A2 and to a lesser extent by CYP3A4 
(Kaye and Nicholls, 2000), whereas the metabolic pathways for pramipexole are not yet clear 
(Agundez et al., 2013). A polymorphism of the gene encoding the solute carrier protein SLC22A1 
(SNP-Id: rs622342) was linked to higher doses of pramipexole and reduced survival time after 
initiation of L-dopa therapy (Becker et al., 2011). These effects may be caused by reduced drug 
uptake from the small intestine. 
 
Ligands of α2δ subunit of voltage-gated calcium channels 
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Mutations and deletions of the CACNA2D1 gene coding for the α2δ subunit family, which has 
five isoforms targeted by gabapentin and pregabalin, were linked to several medical disorders and 
increased sensitivity to opioid treatment (Rhodin et al., 2013). Moreover, a CACNA1A mutation in 
mice leading to impaired G protein-coupled inhibition was associated with reduced sleep induction 
by adenosine and wake promotion by caffeine (Deboer et al., 2013). Interestingly, recent evidence 
indicates that genetic variants of CACNA1C are associated with sleep latency and sleep quality (Byrne 
et al., 2013; Parsons et al., 2013). It may, thus, be expected that such polymorphisms modulate the 
efficacy of drugs or environmental influences that affect sleep. 
Gabapentin-like compounds undergo negligible metabolism and are primarily eliminated as 
unchanged drug by renal excretion. The c.1507C>T polymorphism (SNP-Id: rs1050152) of the gene 
encoding the solute carrier protein SLC22A4 affects gabapentin transport in vitro, yet homozygous 
T-allele carriers showed no enhanced renal clearance of gabapentin when compared to carriers of 
the ‘wildtype’ C-allele (Urban et al., 2007). 
 
Pharmacogenetic Dissection of Sleep-Wake Circuitries in Humans 
As mentioned above, converging lines of research employing optogenetic and chemogenetic 
methods in animal models have pointed to new structures and pathways regulating sleep and 
wakefulness. For example, dopaminergic signaling appeared for a long time to have no crucial role in 
sleep-wake regulation. Accumulating evidence now suggests that antagonistic adenosinergic-
dopaminergic interactions particularly in the striatum play important roles in sleep-wake regulation 
(for reviews, see, Lazarus et al., 2017; Wisor, 2018). Based on this evidence, A2A-D2 receptor positive 
striatopallidal cells may serve as new target for therapeutic intervention in sleep-wake disorders. 
Preclinical human pharmacology provides a bridge between basic (sleep-wake) research and clinical 
(sleep-wake) medicine and is an essential step in the development of novel (sleep-wake) 
therapeutics. 
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Rational treatments of sleep-wake disorders should strengthen the physiological processes 
underlying sleep-wake regulation. According to this rationale, an ‘ideal’ novel hypnotic can be 
expected to promote the same physiological processes that underlie elevated sleep need and 
increased sleep intensity, as reflected by the prevalence of theta/alpha (~ 6-10 Hz) and delta (< 4 Hz) 
frequency activity in the electroencephalogram (EEG) in wakefulness and sleep. Sleep deprivation, 
the strongest challenge of the sleep-wake dependent, homeostatic facet of sleep-wake regulation, 
not only alters in highly predictable fashion electrical brain activity in these frequencies, but also 
impairs a wide range of measures derived from neurobehavioral performance tasks. In the 
laboratory, neurobehavioral deficits of sleep deprivation are accurately indexed by increased lapses 
and slowed reaction times on the psychomotor vigilance task (PVT). This task has been considered a 
gold-standard measurement of sustained vigilant attention in sleep-wake research (Lim and Dinges, 
2010). Performance on the PVT is reliably impaired by elevated sleep need and reflect distinct 
changes in neuronal activity (Nir et al., 2017; Maire et al., 2018). Importantly, these consequences of 
sleep deprivation vary widely among individuals, and are in part genetically determined (Van Dongen 
et al., 2004; Lim et al., 2012). Intriguingly, however, the neurophysiological and neurobehavioral 
variables do not typically show a clear association with each other, but rather develop seemingly 
independently. Thus, it has been suggested that the neurophysiological and neurobehavioral 
consequences of sleep loss are likely governed by separate mechanisms. In the following section, an 
experimental pharmacogenetic approach to systematically dissect these sleep-wake regulatory 
processes in healthy humans will be outlined. Collectively, the results demonstrate distinctly 
different roles for adenosinergic and dopaminergic pathways in the regulation of sleep-wake 
dependent neurophysiological and behavioral functions of the brain. 
 
ADOAR2A gene variants contribute to caffeine sensitivity and neurophysiological and behavioral 
effects of sleep deprivation 
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Through competitive blockade of adenosine A1 and A2A receptors in the central nervous 
system, caffeine attenuates the build-up of sleep pressure during wakefulness and delays the 
endogenous circadian clock (Landolt et al., 2004; Burke et al., 2015). The interference with these 
physiological sleep-wake regulatory mechanisms can disturb the quality of sleep (Clark and Landolt, 
2017). The heritability of coffee attributed sleep disturbances equals roughly 40 % (Luciano et al., 
2007). Caffeine is the major psychostimulant ingredient of coffee (Fredholm et al., 1999), whereas 
blockade of A2A receptors is responsible for the wake-promoting action of caffeine (Huang et al., 
2005). The human ADORA2A gene is located on chromosome 22q11.2, and functional genetic 
variation of ADORA2A is an important determinant of sleep disruption by caffeine. More specifically, 
a combined sleep deprivation and caffeine study provided evidence that the c.1976T>C 
polymorphism of ADORA2A (SNP-ID: rs5751876) modulates individual sensitivity to subjective and 
objective effects of caffeine on sleep (Rétey et al., 2007). Remarkably, this notion was confirmed in a 
large GWA study in 2’402 twins and their families (Byrne et al., 2012). The polymorphism rs5751876 
forms linkage-disequilibria with several other variants of ADORA2A that modulate actions of caffeine 
on sleep and attentional domains that are commonly impaired by sleep deprivation (Bodenmann et 
al., 2012; Renda et al., 2015). In addition, caffeine sensitive and insensitive individuals appear to be 
differently affected by sleep loss (Rétey et al., 2006). This observation supports the notion that the 
functional state of A2A receptors determines the accumulation of sleep need during prolonged 
wakefulness, both in mice and humans (Hayaishi et al., 2004; Bodenmann et al., 2012; Landolt et al., 
2012; Rupp et al., 2013). 
 
Adenosine A2A receptors, dopamine transporters and dopamine D2 receptors are co-localized in the 
striatum 
The distribution of adenosine receptors in the central nervous system is highly 
heterogeneous. The A2A receptor subtype is primarily expressed in the striate nuclei (caudate 
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nucleus, putamen, nucleus accumbens [NAc], globus pallidus) and olfactory tubercle (Figure 2). 
Accumulating evidence suggests that the striatum, the NAc in particular, plays critical roles in wake 
promotion by caffeine and in sleep-wake regulation (Lazarus et al., 2011; Zhang et al., 2013; Holst 
and Landolt, 2015). Apart from widespread glutamatergic inputs from several cortical and 
subcortical areas, the striatum receives dopaminergic inputs via axons originating in the substantia 
nigra pars compacta and the ventral tegmental area (VTA) of the brainstem. Extracellular dopamine 
levels in NAc and medial PFC fluctuate across sleep-wake states in rats (Lena et al., 2005). Combined 
behavioral, chemogenetic and optogenetic manipulations in freely moving mice suggest a 
fundamental role for the VTA dopaminergic circuitry in maintaining wakefulness and linking 
motivated behaviors with sleep-wake regulation (Eban-Rothschild et al., 2016; Oishi et al., 2017a). 
Similar to adenosine A2A receptors, also the dopamine re-uptake transporter (DAT) is highly 
expressed in the striatum (Figure 2). The DAT transports extracellular dopamine from the synaptic 
cleft into the pre-synaptic terminals for repackaging into vesicles. The deletion of the dat gene in 
mice reduces NREM sleep time and increases wakefulness (Wisor et al., 2001). Intriguingly, the Dat-/- 
knock-out mice are hypersensitive to the wake-promoting effects of caffeine. More specifically, 
relative to wildtype littermates, the knock-out animals exhibit a 3- and 5-fold greater increase in 
wake time after 2.5 and 10 mg/kg caffeine administration when compared to vehicle (Wisor et al., 
2001). Based on these data in animals, it was hypothesized that functional variance not only in 
CYP1A2 and ADORA2A (see above) but also in the DAT1 gene may modulate the response to caffeine 
in humans. 
 
DAT1 genotype modulates caffeine sensitivity and neurophysiological and behavioral effects of sleep 
deprivation 
The human DAT1 gene contains a common VNTR polymorphism in its 3’-untranslated region. 
Linkage and associations of this polymorphism (SNP-ID: rs28363170) with various psychiatric 
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disorders (e.g., attention-deficit-hyperactivity disorder, PD, alcoholism, schizophrenia) have been 
reported, suggesting that it is functionally relevant (Pinsonneault et al., 2011). In addition, in vitro 
studies revealed an effect of this polymorphism on gene expression (Pinsonneault et al., 2011). The 
VNTR can exist in forms of 3 to 13 repeats, but two alleles are most common: 9 repeats (9R) or 10 
repeats (10R) of a 40-bp sequence in exon 15. Several studies in humans quantified striatal DAT 
availability with SPECT (single photon emission computer tomography) and PET (positron emission 
tomography): these studies consistently reported lower striatal DAT binding in 10R homozygotes 
when compared to 9R allele carriers. On average, 10R homozygotes exhibit 10-15 % lower striatal 
DAT availability than 9R allele carriers (Costa et al., 2011; Faraone et al., 2014). Are 10R 
homozygotes, thus, more sensitive to caffeine than 9R carriers, analogous to Dat-/- mice? 
This seems to be the case. In a survey among 485 individuals, a significantly larger 
proportion of 10R homozygotes (39 %) rated themselves as being sensitive to psychostimulant 
action of caffeine when compared to 9R allele carriers (Holst et al., 2014). In the case of 9R 
homozygotes, only 2 out of 23 individuals (9 %) were caffeine sensitive. The respective number was 
33 % in 9R/10R heterozygotes. A subsequent controlled study in the laboratory confirmed that the 
DAT1 VNTR predicts the effect of caffeine on EEG markers of sleep need. The stimulant attenuated 
the rebound in EEG slow waves following prolonged wakefulness in DAT1 10R homozygotes only 
(Holst et al., 2014). From the perspective of sleep-wake regulatory mechanisms, it is important to 
note that this polymorphism associated with the repercussions of sleep deprivation on sleep EEG 
markers of increased sleep drive (Holst et al., 2014). In addition, it modulated time-on-task effects 
and performance instability on the PVT, as well as on the effects of the DAT inhibitor, modafinil, on 
markers of sleep need (Lim et al., 2012; Holst et al., 2014; Satterfield et al., 2017). Taken together, 
convergent findings in animals and humans suggest that A2A receptors and DAT are involved in the 
wake-promoting effects of caffeine and modafinil. They further indicate that adenosine-dopamine 
interactions in the striatum are important for sleep-wake regulation and the behavioral 
consequences of sleep deprivation. 
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DRD2 genotype modulates neurophysiological and neurobehavioral consequences of sleep 
deprivation 
Increasing evidence demonstrates the presence of co-expressed A2A-D2 receptor complexes 
on distinct subpopulations of medium spiny neurons, the principle neuronal cell type of the dorsal 
and ventral striatum (Azdad et al., 2009; Ferre et al., 2010; Casado-Anguera et al., 2016). Indeed, 
brain imaging demonstrates that D2 receptors are mainly expressed in the striatum (Figure 2). 
Striatal outputs are primarily composed of two types of projection neurons: indirect medium spiny 
neurons (iMSNs) that express D2-type receptors and direct medium spiny neurons expressing D1-
type receptors (Ferre et al., 2010; Yager et al., 2015). Activation of iMSNs causes a net inhibition of 
the thalamus, which is part of the fronto-striatal circuit (Yager et al., 2015). Brain imaging of human 
subjects while performing a working memory task revealed that gene variants encoding DAT and D2 
receptor proteins interact to regulate fronto-striatal circuit activity (Bertolino et al., 2009). 
Moreover, striatal D2 receptor availability after sleep deprivation is reduced when compared to 
baseline (Volkow et al., 2012) and regulates brain activation during performance of a visual attention 
task (Tomasi et al., 2016). 
The DRD2 gene includes a functional c.957C>T polymorphism (SNP-ID: rs6277) that affects 
levels and stability of mRNA such that C-allele carriers exhibit 15–20% enhanced striatal D2 receptor 
availability when compared to T-allele carriers (Hirvonen et al., 2009). This polymorphism alone and 
in interaction with the presence of either 9R and 10R alleles of DAT1 was found to modulate the 
evolution of waking EEG markers of accumulating sleep pressure, subjective sleepiness, as well as 
performance on the PVT across prolonged waking (Holst et al., 2017). More specifically, individuals 
homozygous for the C allele of DRD2 and the 10R allele of DAT1 were more severely affected with 
attentional lapses after 40 hours of wakefulness than other genotypic variants. A recent study 
confirmed that homozygous carriers of the C allele of the DRD2 c.957C>T polymorphism are 
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impaired by sleep deprivation in vigilant attention (Whitney et al., 2017). Remarkably, however, the 
same individuals were resilient to the effects of prolonged waking on reversal learning, a measure of 
cognitive flexibility (Whitney et al., 2017). Consistent with the notion that the consequences of sleep 
deprivation are trait-like but task-specific, the data collectively suggest that striato-thalamo-cortical 
dopaminergic pathways contribute to the regulation of neurophysiological and neurobehavioral 
consequences of sleep loss in humans. 
 
COMT genotype modulates neurobehavioral consequences of sleep deprivation without affecting 
neurophysiological markers of elevated sleep need 
The COMT gene encodes the main enzyme degrading catecholamines in the PFC, COMT, 
which regulates dopaminergic neurotransmission by converting DA to 3-methoxytyramine 
(Matsumoto et al., 2003). The genotype of the Val158Met polymorphism of COMT (SNP-Id: rs4680) 
has a consistent impact on PFC functioning (Egan et al., 2001; Tunbridge et al., 2006; Bodenmann et 
al., 2009b). Nevertheless, some effects of this genetic variant only become apparent when the DA 
system is challenged, such as after sleep deprivation (Bodenmann et al., 2009a; Satterfield et al., 
2018; Valomon et al., 2018). More specifically, Val/Val, Val/Met and Met/Met allele carriers perform 
similarly in baseline. Yet, after a night without sleep, Val/Met heterozygotes produced twice as many 
attentional lapses than Met/Met homozygotes (Valomon et al., 2018). Furthermore, the wake-
promoting agent modafinil is virtually ineffective in mitigating impaired PVT performance after sleep 
loss in Met/Met homozygotes. By contrast, in homozygous Val/Val allele carriers, the same dose of 
modafinil maintains virtually optimal performance throughout 40 h of wakefulness (Bodenmann et 
al., 2009a). 
To test the hypothesis that PFC dopaminergic signaling regulated by COMT causally 
contributes to neurobehavioral and neurophysiological markers of sleep loss, the interaction of 
COMT genotype, tolcapone and sleep deprivation on lapses of attention and neurophysiological 
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markers of sleep-wake regulation was investigated in a controlled laboratory study. Tolcapone is a 
brain penetrant inhibitor of COMT that leads to specific increases in PFC dopaminergic tone without 
affecting striatal dopaminergic transmission (Farrell et al., 2012). It was expected that tolcapone 
would mitigate the effects of sleep deprivation primarily in Val/Val homozygotes because it 
counteracts the overactive COMT and associated deficit in PFC dopaminergic function. 
Unexpectedly, tolcapone had no beneficial effect in any COMT genotype. By contrast, it increased 
attentional lapses even further, particularly in Val/Met and Met/Met allele carriers (Valomon et al., 
2018). The data suggest an inverted U-shape relationship between PFC dopaminergic signaling and 
sustained attention after sleep loss. They further demonstrate that beyond and above COMT 
genotype, a pre-existing sleep debt strongly impacts on the effects of a pharmacological increase of 
dopaminergic neurotransmission on brain functions. 
In contrast to these behavioral effects, genetically determined and pharmacologically 
induced differences in COMT activity do not affect established EEG markers of elevated sleep 
pressure in wakefulness and sleep challenged by acute total sleep deprivation (Bodenmann and 
Landolt, 2010; Valomon et al., 2018). 
 
Experimental human pharmacogenetics: converging evidence for distinct adenosinergic/ 
dopaminergic pathways mediating neurophysiological and behavioral consequences of sleep loss 
Among the four major dopaminergic pathways in the brain, three pathways originating in 
the midbrain are especially important for interpreting the findings discussed above. They consist of 
the nigrostriatal pathway projecting from the substantia nigra to the dorsal striatum (caudate 
nucleus and putamen), which is involved in motor control; the mesolimbic pathway originating in the 
VTA and innervating several structures of the limbic system (including the NAc), which is associated 
with reward cognition, reinforcement and motivational salience; and the mesocortical pathway, also 
originating in the VTA yet having widespread projections to the cerebral cortex, being essential for 
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normal cognitive functions of the dorso-lateral PFC, attentional control, motivation and emotional 
processes. The regulation of DA metabolism and uptake and, thus, dopaminergic neurotransmission 
depends on the different pathways, such that DAT and D2 receptors regulate 
nigrostriatal/mesolimbic circuit activity, while COMT controls dopaminergic transmission in the 
mesocortical pathway. 
Taken together, the systematic human pharmacogenetic dissection of adenosine-associated 
loci and dopamine-related loci demonstrates that the distinct signaling pathways differently 
modulate the response to sleep loss and wake-promoting agents on neurophysiological markers of 
sleep need and neurobehavioral deficits (Figure 3). The ADORA2A c.1976T>C polymorphism (Rétey 
et al., 2007; Rupp et al., 2013), an ADORA2A haplotype (Bodenmann et al., 2012), the DAT1 VNTR 
polymorphism (Holst et al., 2014; Satterfield et al., 2017), and the DRD2 c.957C>T polymorphism 
(Holst et al., 2017; Whitney et al., 2017) modulate both, EEG and distinct behavioral markers of 
elevated sleep need and the effects of caffeine and modafinil on these markers. The findings suggest 
that striatal iMSNs, which co-express high densities of adenosine A2A and dopamine D2 receptors 
mediate these consequences of sleep loss. It is tempting to speculate that the NAc is essential in 
these processes. Thus, elegant studies in animal models have demonstrated that caffeine and 
modafinil promote wakefulness by blocking A2A receptors on GABAergic neurons of the NAc that co-
express A2A and D2 receptors (Lazarus et al., 2011; Qiu et al., 2016; Oishi et al., 2017b). These 
neurons have major projections to the ventral pallidum and may induce sleep by inhibiting the 
ascending arousal pathways and the thalamus. 
In contrast to ADORA2A, DAT1 and DRD2, genetic variation of COMT did not impact on 
neurophysiological markers of sleep need (Bodenmann et al., 2009a; Valomon et al., 2018). 
Nevertheless, COMT genotype and pharmacologic interference with PFC dopaminergic tone with 
modafinil and tolcapone consistently affect the consequences of sleep loss on PVT lapses 
(Bodenmann et al., 2009a; Valomon et al., 2018). Given that tolcapone leaves striatal dopaminergic 
neurotransmission unaltered, this finding strongly indicates that the mesocortical pathway 
Landolt et al. Human Sleep-Wake Pharmacogenetics 
30 
contributes to the regulation of attentional lapses during prolonged wakefulness without affecting 
sleep-wake regulatory mechanisms. 
 
Concluding Remarks 
Prospects of Pharmacogenetics for Personalized Sleep-Wake Medicine and New Drug Discovery 
Not only gene polymorphisms, but a host of environmental factors, including epigenetics, as 
well as co-morbidity and co-medications, cause variability in expression and function drug targets 
and pharmacokinetic processes in each individual. The genotyping of single genes is, thus, of limited 
use for guiding individual pharmacotherapy. Rather, the implementation of deep phenotyping 
strategies to test individual target and enzyme functions likely provides a more promising approach 
to achieve personalized dosing of sleep-wake drugs (e.g., (Hohmann et al., 2016; Urry et al., 2016)). 
Powerful new tools to interrogate sleep-wake regulating circuits have revealed new 
molecular and cellular markers, as well as novel network mechanisms and pathways that regulate 
wakefulness and sleep. While the ascending arousal system was first described as a reticular 
network of neurons projecting widely to the cortex and the spinal cord (Moruzzi and Magoun, 1949), 
it has become clear in the last few years that wakefulness and sleep are governed by distinct 
populations and subtypes of neurons (Varin and Bonnavion, 2018). Although specific, these neuronal 
systems are often redundant and reinforce each other. Future research should clarify their causal 
associations with sleep homeostasis and the circadian clock, as well as sleep and circadian rhythm 
disturbances, in humans. For example, it should be clarified whether A2A-D2 receptor positive 
striatopallidal neurons regulate sleep homeostasis, or rather promote sleep in the absence of 
motivational stimuli (cf. (Oishi et al., 2017b)). Such studies may identify critical targets within newly 
identified sleep and circadian pathways for pharmacological interventions. 
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Legends to the Figures 
Figure 1. Schematic representation of sleep-wake disorders according to the International 
Classification of Sleep Disorders (ICSD) currently amenable to pharmacotherapy for improved 
sleep and wake state (thus excluding sleep-related breathing disorders). Blue shading: drugs used to 
improve sleep in insomnia disorder, parasomnias, and circadian rhythm sleep-wake disorders. Red 
shading: drugs to improve wake state in central disorders of hypersomnolence. Green shading: drugs 
to reduce periodic limb movements in sleep (PLMS) in sleep-related movement disorders. Mel = 
melatonin; MT1/2 = melatonin MT1 and MT2 receptors; 5-HT = serotonin; 5-HT2C = serotonin-2C 
receptor; GABA = γ-amino-butyric acid; GABAA = GABAA receptor; GABAB = GABAB receptor; His = 
histamine; H1 = histamine H1 receptor; H3 = histamine H3 receptor; VGCC = voltage-gated calcium 
channel; DA = dopamine; DAT = dopamine transporter; D2/3/4 = dopamine D2, D3 and D4 receptors; 
Ado = adenosine; A1/2A = adenosine A1 and A2A receptors; NE = norepinephrine; Hcrt = hypocretin. 
↑ amplification of neurotransmission; ↓ inhibition of neurotransmission 
Figure 2. A2A receptors, dopamine transporters (DAT), and D2 receptors are co-localized on dorsal 
and ventral striatal neurons. The distribution volumes (color-coded) of selective radioligands that 
bind to these receptors and transporters on the level of the basal ganglia in humans were 
reconstructed with single photon emission computer tomography (123I-MNI 420) and positron 
emission tomography (11C-cocaine and 11C-raclopride) imaging. The Figure has been composed of 
published data by (Seibyl et al., 2012) and (Volkow et al., 2012). 
Figure 3. Pharmacogenetic dissection of adenosinergic-dopaminergic pathways with caffeine (A2A 
receptor antagonist), modafinil (DAT inhibitor), and tolcapone (COMT inhibitor) reveal different 
contributions of dopaminergic pathways to sleep-wake regulation and behavioral consequences of 
sleep loss. The mesolimbic/nigrostriatal dopaminergic pathway (blue) regulates neurophysiological 
markers of sleep homeostasis in wakefulness and sleep and contributes to impaired sustained 
attention. Together with animal studies, findings support the notion that the nucleus accumbens, 
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which expresses high densities of dopamine D2 and adenosine A2A receptors, may be an essential 
player in these functions. The mesocortical dopaminergic pathway (red) does not affect 
neurophysiological markers of sleep deprivation. COMT = catechol-O-methyltransferase. DAT = 
dopamine transporter. 
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Table 1. Currently available pharmacological treatments of sleep-wake disorders. 
Drug class Approved 
compound 
Sleep-wake 
indication(s) 
Wanted sleep-wake 
effect(s) 
Main mode of action 
for sleep-wake effect 
Main metabolism/ 
excretion pathways 
Benzodiazepines Quazepam 
Estazolam 
Flurazepam 
Triazolam 
Temazepam 
Clonazepam 
Insomnia 
 
 
 
 
Parasomnias 
Improved sleep Positive agonistic 
modulation of GABAA 
receptors 
CYP3A4/5, CYP2C19, 
UGT isoenzymes, NAT2 
Z-drugs Zolpidem 
(Es)Zopiclone 
Zaleplon 
Insomnia Improved sleep Positive agonistic 
modulation of GABAA 
receptors 
CYP3A4, aldehyde 
oxidase 
Barbiturates Butabarbital 
Secobarbital 
Insomnia (rarely used) Improved sleep GABAA receptor 
agonism 
CYP1A2, CYP2C9/10, 
CYP3A4 
 Sodium oxybate Narcolepsy Reduced cataplexy and 
improved wake state (EDS) 
GHB/GABAB receptor 
agonism 
GHB dehydrogenase → 
succinic acid → Krebs 
cycle → CO2 exhalation 
DORA Suvorexant Insomnia Improved sleep Hcrt-1/2 receptor 
antagonism 
CYP3A4/5, CYP2C19 
Antihistamines Diphenhydramine 
Doxylamine 
(Insomnia) 
 
Improved sleep H1 receptor antagonism CYP2D6, CYP1A2, 
CYP2C9 
TCA Doxepine Insomnia Improved sleep H1 receptor antagonism CYP2D6, CYP2C19 
TeCA Mirtazapine Insomnia Improved sleep H1 receptor antagonism, 
5-HT2A antagonism 
CYP2D6, CYP1A2, 
CYP3A4 
Melatonin Melatonin/Circadin® Adult insomnia ≥ 55 y; Improved sleep and wake MT1/2 receptor agonism CYP1A2 → Sulpha-
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Drug class Approved 
compound 
Sleep-wake 
indication(s) 
Wanted sleep-wake 
effect(s) 
Main mode of action 
for sleep-wake effect 
Main metabolism/ 
excretion pathways 
agonists (prolonged release) 
 
Ramelteon 
 
Tasimelteon 
 
Agomelatine 
N24HSWD; DSPD; tran-
sient insomnia; SAD 
Sleep onset insomnia 
in older adults 
N24HSWD; transient 
insomnia 
MDD 
state 
 
Improved sleep 
 
Improved sleep and wake 
state 
Antidepressant/anxiolytic, 
beneficial effect on sleep 
 
 
MT1/2 receptor agonism 
 
MT1/2 receptor agonism 
 
5-HT2C antagonism/ 
MT1/2 receptor agonism 
methoxymelatonin 
(urine), CYP3A4 
CYP1A2, CYP3A4 
 
CYP1A2, CYP3A4 
 
CYP1A2, CYP3A4 
Psychostimulants Methylphenidate 
Methamphetamine 
 
 
Caffeine 
Narcolepsy 
 
 
 
n/a 
Improved wake state (EDS) NET-DAT inhibition 
NE, DA, and 5-HT 
release NET-DAT 
inhibition 
 A1/2A receptor 
antagonism 
CES1 
Urinary excretion as 
parent drug and/or 
D-amphetamine 
CYP1A2 
 
Wake promoting 
agents 
(Ar)Modafinil Narcolepsy, shiftwork 
sleep disorder, OSA 
Improved wake state (EDS) Unknown, DAT 
inhibition  
Amide hydrolysis, CYP-
mediated oxygenation 
5-HT/NE re-
uptake inhibitor 
Venlafaxine MDD, narcolepsy Reduced cataplexy SERT/NET inhibition CYP2D6 
H3 inverse agonist Pitolisant Narcolepsy Improved wake state (EDS) 
and reduced cataplexy 
H3 receptor inverse 
agonism 
CYP3A4, CYP2D6 
D2 agonists Pramipexole 
 
Ropinirole 
Rotigotine 
PD, RLS Reduction of PLMS D2/3/4 receptor agonism Urinary excretion of 
unchanged drug (> 90 %) 
CYP1A2 
CYP2C19, UGT enzymes 
 Gabapentine RLS, insomnia Reduction of PLMS, 
improved sleep 
Unknown, binding to 
α2δ subunit of VGCC 
Urinary excretion of 
unchanged drug 
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DORA = dual orexin receptor antagonists; TCA = tricyclic antidepressants; TeCA = tetracyclic antidepressants; 5-HT = 5-hydroxytryptamine, serotonin; NE = 
norepinephrine; H3 = histamine H3 receptor; Hcrt = hypocretin; D2 = dopamine D2 receptor; N24HSWD = non-24-hour sleep-wake disorder; DSPD = delayed 
sleep phase disorder; SAD = seasonal affective disorder; MDD = major depressive disorder; OSA = obstructive sleep apnea; PD = Parkinson’s disease; RLS = 
restless legs syndrome; EDS = excessive daytime sleepiness; PLMS = periodic limb movements in sleep; GHB = γ-hydroxybutyrate; H1 = histamine H1 
receptor; MT1/2 receptors = melatonin MT1 and MT2 receptors; 5-HT2A = serotonin-2A receptors; 5-HT2C = serotonin-2C receptors; DAT = dopamine 
transporter; SERT = serotonin transporter; NET = norepinephrine transporter; A1/2A receptors = adenosine A1 and A2A receptors; VGCC = voltage-gated 
calcium channels; CYP = cytochrome-P450 isoenzymes; UGT = uridine-5’-diphospho-glucuronyltransferase; NAT2 = N-acetyltransferase 2; CES1 = 
carboxylesterase 1; COMT = catechol-O-methyltransferase; MAOB = monoaminoxidase type-B. 
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